Safety Study to Assess Whether Proinsulin Peptide Injections Can Slow or Stop the Body Damaging Its Own Insulin-making Cells in the Pancreas in Patients Newly Diagnosed With Type 1 Diabetes

Type 1 Diabetes Clinical Trial

— MonoPepT1De  

Official title:

Phase 1b Study of Proinsulin (PI) Peptide Immunotherapy in New-Onset Type 1 Diabetes

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01536431
• Other study ID #: SPON817-10
• Secondary ID: 2007-003759-3566
• Status: Completed
• Phase: Phase 1/Phase 2
• First received: February 14, 2012
• Last updated: July 27, 2015
• Start date: January 2012
• Est. completion date: February 2015

Study information

• Verified date: July 2015
• Source: Cardiff University
• Contact: n/a
• Is FDA regulated: No
• Health authority: United Kingdom: Medicines and Healthcare Products Regulatory Agency
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to address the safety issue of whether, in patients with newly−diagnosed diabetes who still make some insulin, proinsulin peptide therapy adversely affects the rate of damage to the insulin making cells.

Description:

Type 1 Diabetes (also known as insulin−dependent diabetes) is caused by destruction of the insulin producing cells (Beta Cells) in the pancreas. Our group is interested in how this destruction could be stopped or reversed, as this may lead to development of a new generation of diabetes treatments which can prevent or slow down the damage, reducing or possibly even removing there need for insulin injections.

In a previous study we examined the safety of our novel approach to this problem, proinsulin (PI) peptide immunotherapy, in longstanding diabetes patients (diagnosed more than 5 years before), and found it to be well tolerated and free of major hypersensitivity reactions. However, it remains theoretically possible that this form of immunotherapy could make the immune reaction to the insulin making cells worse rather than better.

This cannot be studied directly in longstanding patients as they have no or almost no insulin making cells left.

So,the principle objective of the current study is to address the safety issue of whether, in patients with newly−diagnosed diabetes who still make some insulin, proinsulin peptide therapy adversely affects the rate of damage to the insulin making cells.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 27
• Est. completion date: February 2015
• Est. primary completion date: February 2015
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 40 Years

Eligibility

Inclusion Criteria:

1. Age 18-40 years.

2. If female, must be (as documented in patient notes):

• postmenopausal (at least 1 year without spontaneous menses)

• surgically sterile (tubal ligation or hysterectomy at least 6 months prior to enrolment)

• using acceptable contraception (e.g., oral, intramuscular, or implanted hormonal contraception) at least 3 months prior to enrolment

• have a sexual partner with non-reversed vasectomy (with confirmed azoospermia)

• be using 1 barrier method with the use of a spermicide(e.g., condom, diaphragm or cap)

• have placement of a intra-uterine device

3. If male, must be:

• using a barrier method of contraception (condom) with the use of a spermicide

• have a sexual partner using one of the methods in point 2 above or

• have a non-reversed vasectomy (with confirmed azoospermia),

4. Diagnosis of Type 1 diabetes within the last 100 days (dated from the first insulin injection).

5. Possession of *0401 allele at the HLA-DRB1 gene locus

6. At least one positive islet cell autoantibody (ie anti-GAD65, antibodies to insulinoma-associated antigen-2 (IA-2) or zinc transporter 8 (ZnT8)).

7. Peak insulin C-peptide >200 pmol/L (at any time point after stimulation with Mixed Meal Tolerance Test).

8. Written and witnessed informed consent to participate.

Exclusion Criteria:

1. Females who are pregnant, breast-feeding or not using adequate forms of contraception.

2. Use of immunosuppressive or immunomodulatory therapies, including systemic steroids within 1 month prior to randomisation and any monoclonal antibody therapy given for any indication.

3. Any other medical condition which, in the opinion of investigators, could affect the safety of the subject's participation.

4. Recent subject's involvement in other research studies which, in the opinion of investigators, may adversely affect the safety of the subjects or the results of the study.

5. Subjects should not have had immunisations with live or killed vaccines or allergic desensitisation procedures less than 1 month prior to their first treatment.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Diabetes Mellitus, Type 1
• Type 1 Diabetes

Intervention

Drug:
• Pro insulin peptide
Patients will receive 10 micro gr of the peptide every 2 weeks (12 doses).
• Pro insulin peptide
Patients will receive 10 micro gr of the peptide monthly (ever 4 weeks, 6 doses) and saline injections monthly alternating with the peptide (2 weeks interval between the drug and saline).
• Saline
Patients will receive 0 micro gr of peptide, but have saline injections every 2 weeks (controls).

Locations

Country	Name	City	State
United Kingdom	Bristol Royal Infirmary	Bristol
United Kingdom	University Hospital of Wales	Cardiff
United Kingdom	Countess of Chester	Chester	England
United Kingdom	Guy's Hospital	London
United Kingdom	Royal Victoria Hospital	Newcastle

Sponsors (3)

Lead Sponsor	Collaborator
Cardiff University	Diabetes Vaccine Development Centre, Juvenile Diabetes Research Foundation

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety	To address the safety issue of whether, in patients with newly-diagnosed diabetes who still make some insulin, proinsulin peptide therapy adversely affects the rate of damage to the insulin making cells.	3 years	Yes
Secondary	Allergy and hypersensitivity	To confirm that PI peptide treatment does not induce allergy or hypersensitivity and has a good safety profile in new-onset type 1 diabetes patients.	3 years	Yes
Secondary	Safety of frequent dosing	To explore the safety of extending peptide treatment to more frequent dosing (2-weekly) and for a longer time period (6 months)	3 years	Yes
Secondary	Protective effects of insulin preservation	To provide preliminary data on any protective effect on preservation of insulin production after 1 year of treatment	3 years	No
Secondary	T cell (immune) response to islet cell antigens	To provide preliminary data on changes in the T cell (immune) response to islet cell antigens in newly-diagnosed patients following PI peptide treatment.	3 years	No

External Links

•   Cardiff University, School of Medicine, Diabetes & Endocrinology Clinical Trials